The post describes tirzepatide as a dual GLP-1 and GIP receptor agonist that increases insulin sensitivity, slows gastric emptying and reduces appetite, while the lipotropic components are aimed separately at fat mobilization
Debunking the myth: Broader application: While GLP-1 agonists were originally developed for the treatment of type 2 diabetes, their benefits extend beyond blood sugar control
Rapid weight loss can alter biomechanics and centre of gravity, requiring postural adaptation that may cause temporary muscular strain in the lumbar region
It also participates in the synthesis of NO and carnitine, and may increase prostacyclin levels
This method provides quick relief by allowing essential nutrients to be absorbed faster than through oral methods, helping alleviate symptoms like fatigue, dehydration, and body aches